BACKGROUND: The aim of the study was to investigate mortality following transcatheter mitral valve repair with the MitraClip System (MC) (Abbott Vascular, Santa Clara, CA, USA) in patients with mitral regurgitation and moderate-to-severe symptomatic heart failure in comparison to mortality predicted by the Seattle Heart Failure Model (SHFM) and the heart failure calculator of the meta-analysis global group in chronic heart failure (MAGGIC). METHODS AND RESULTS: This retrospective study included 194 consecutive patients, who received a MC implantation between 2009 and 2013 at our institution. The observed mortality was compared with that predicted by the SHFM and the MAGGIC after 1 year: 24% observed, 18% by SHFM (p=0.185) and 20.9% by MAGGIC (p=0.542). At 2 years: 32% observed vs. 33% by SHFM (p=0.919). The subgroup of patients with end-stage heart failure and N-terminal pro-B-type natriuretic peptide (NTproBNP) >10,000pg/ml (n=41) had significantly worse mortality after 1 year (49%) than predicted by SHFM (24%, p=0.034) and MAGGIC (24.8%, p=0.041). CONCLUSION: In the overall patient cohort defined by 3+ to 4+ mitral valve regurgitation with New York Heart Association III and IV symptomatic heart failure, mortality following MC is consistent with that predicted by SHFM and MAGGIC for patients that are not at high risk. However, the subset of patients with severe heart failure defined by NTproBNP >10,000pg/ml had worse than predicted mortality and may not benefit from MC therapy, mainly due to a high 30-day mortality.
BACKGROUND: The aim of the study was to investigate mortality following transcatheter mitral valve repair with the MitraClip System (MC) (Abbott Vascular, Santa Clara, CA, USA) in patients with mitral regurgitation and moderate-to-severe symptomatic heart failure in comparison to mortality predicted by the Seattle Heart Failure Model (SHFM) and the heart failure calculator of the meta-analysis global group in chronic heart failure (MAGGIC). METHODS AND RESULTS: This retrospective study included 194 consecutive patients, who received a MC implantation between 2009 and 2013 at our institution. The observed mortality was compared with that predicted by the SHFM and the MAGGIC after 1 year: 24% observed, 18% by SHFM (p=0.185) and 20.9% by MAGGIC (p=0.542). At 2 years: 32% observed vs. 33% by SHFM (p=0.919). The subgroup of patients with end-stage heart failure and N-terminal pro-B-type natriuretic peptide (NTproBNP) >10,000pg/ml (n=41) had significantly worse mortality after 1 year (49%) than predicted by SHFM (24%, p=0.034) and MAGGIC (24.8%, p=0.041). CONCLUSION: In the overall patient cohort defined by 3+ to 4+ mitral valve regurgitation with New York Heart Association III and IV symptomatic heart failure, mortality following MC is consistent with that predicted by SHFM and MAGGIC for patients that are not at high risk. However, the subset of patients with severe heart failure defined by NTproBNP >10,000pg/ml had worse than predicted mortality and may not benefit from MC therapy, mainly due to a high 30-day mortality.
Authors: S Heyl; B Luu; M Wieszner; A Nikkhoo; F Seeger; K Hemmann; B Assmus; B Kaess; A M Zeiher; C Walther; S Fichtlscherer; J Honold Journal: Int J Cardiol Heart Vasc Date: 2020-10-12
Authors: David M Kaye; Mark C Petrie; Scott McKenzie; Gerd Hasenfuβ; Filip Malek; Martijn Post; Robert N Doughty; Jean-Noël Trochu; Finn Gustafsson; Irene Lang; Adam Kolodziej; Ralf Westenfeld; Martin Penicka; Mark Rosenberg; Jörg Hausleiter; Philip Raake; Guillaume Jondeau; Martin W Bergmann; Tim Spelman; Huseyin Aytug; Piotr Ponikowski; Chris Hayward Journal: ESC Heart Fail Date: 2018-10-11